Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma

<p>Cue Biopharma&apos;s Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.</p>